Efficacy of Remdesivir in Comparison with Interferon Beta-1 a and Remdesivir in the Treatment of Covid 19
Phase 3
Recruiting
- Conditions
- covid 19.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20200721048159N4
- Lead Sponsor
- Vice Chancellor for Research and Technology of Lorestan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Hospitalized patients suspected to Covid19 infection
SpO2 less than 93%
The presence of respiratory symptoms (including shortness of breath, pain and pressure in the chest)
older than 40 years
Exclusion Criteria
Dissatisfaction with participating in the study
History of severe renal failure
History of allergies to interferon or remdesivir
History of severe liver failure
Pregnancy
Lactation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Duration of hospitalization. Timepoint: 7 -14 days. Method of measurement: Based on patient file information.
- Secondary Outcome Measures
Name Time Method The duration of recovery or the duration of entry into the disease stage. Timepoint: 7-14 days. Method of measurement: Based on patient file information.;Survival rate of 28 days from the time of hospitalization. Timepoint: 28 days after starting the study. Method of measurement: Interview with the patient or her family.;The amount of arterial oxygen saturation. Timepoint: Daily. Method of measurement: Using a device to measure the percentage of oxygen saturation.;Frequency of transfer to intensive care unit. Timepoint: Daily. Method of measurement: Under supervision.